Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 3/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29878128 | 1.00 | BRD9 (0.40) | BRD9MAPTLCKCYP17A1NAMPT | |
| SCHEMBL4726039 | 0.84 | ALDH1A1 (0.47) | MAPT | |
| SCHEMBL29877603 | 0.84 | ALDH1A1 (0.47) | MAPT | |
| SCHEMBL12321293 | 0.81 | MAP4K4 (0.40) | BRD9LCKMETAP1ATR | |
| SCHEMBL29759682 | 0.81 | MAP4K4 (0.40) | BRD9LCKMETAP1ATR | |
| SCHEMBL2068048 | 0.81 | AAK1 (0.48) | BRD9LCKMETAP1ATR | |
| SCHEMBL21783538 | 0.81 | CYP17A1 (0.40) | BRD9LCKCYP17A1METAP1ATR | |
| SCHEMBL2258337 | 0.80 | MAPT (0.42) | MAPTCYP17A1NAMPTATR | |
| SCHEMBL28209587 | 0.80 | BRD9 (0.35) | BRD9MAPTCYP17A1NAMPTMETAP1 | |
| SCHEMBL21339726 | 0.80 | SMN1; SMN2 (0.41) | BRD9MAPTLCKMETAP1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350052-B1 | ANTIPROLIFERATIVE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010034838-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2007056016-A2 | BISAMIDE CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056016-A2 | BISAMIDE CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | BRD9 3297/4885MAPT 3852/4885LCK 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.